Key result
Parenteral iron improves exercise tolerance and quality of life in PAH without affecting hemodynamics.
Why the study?
Iron deficiency is widespread in cardiovascular disease, but there are few studies on the use of iron preparations in patients with pulmonary hypertension.
Do parenteral iron preparations improve symptoms and prognosis in patients with pulmonary arterial hypertension?
Systematic Review
Do parenteral iron preparations improve symptoms and prognosis in patients with pulmonary arterial hypertension?
Parenteral iron therapy in patients with pulmonary arterial hypertension improves exercise tolerance and quality of life without significant hemodynamic changes, and is well tolerated.
Answers are grounded in this paper and cite their sources.
Supports symptomatic use of parenteral iron in PAH; extends limited data but leaves randomized confirmation of outcomes open.
Iron deficiency is widespread in patients with cardiovascular disease. In recent years, the correction of iron deficiency in patients with chronic heart failure has been actively studied to improve the prognosis and course of the disease. Currently, there are not many studies on the use of iron preparations in patients with pulmonary hypertension. The aim of our review was to explore the possibility of using parenteral iron preparations in patients with pulmonary arterial hypertension to improve symptoms and prognosis. The final analysis included 5 publications. According to the results of the presented studies, after the use of iron preparations, laboratory data characterizing iron deficiency were normalized in all patients, exercise tolerance increased, and the quality of life improved. At the same time, according to the indicators of instrumental studies, the parameters were without dynamics, catheterization of the right heart also showed no effect on hemodynamic criteria. In all studies, iron preparations were well tolerated, no serious side effects were detected, which confirms the possibility of widespread use of drugs of this group. Timely diagnosis and treatment of anemia and latent iron deficiency in patients with pulmonary hypertension prevent disease progression. However, at present, in real clinical practice, parenteral iron preparations are rarely used in patients with latent iron deficiency, as a result of which active outreach among practitioners is necessary in order to expand the use of this type of treatment.
No takes yet. Share an insight, caveat, or question.
Balkina et al. (2025) conducted a systematic review in Pulmonary arterial hypertension. Parenteral iron preparations was evaluated on Symptoms, prognosis, laboratory data, exercise tolerance, quality of life, and hemodynamics. Parenteral iron preparations improved exercise tolerance and quality of life across 5 reviewed studies of patients with pulmonary arterial hypertension, without affecting hemodynamic criteria.
Synapse has enriched 10 related papers. Consider them for comparative context: